TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech, a Roche Group company(OTCQX:RHHBY) said on Wednesday that the U.S. FDA accepted the company’s supplemental ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...

Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s ...

Roche, announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such ...